The Human Stem Cell Institute (HSCI) announced the start of clinical trials of a new vaccine against coronavirus infection, Betuvax.
– On Friday, October 15, in St. Petersburg at the A.A. According to the protocol approved by the Ministry of Health, the studies … will be carried out on 170 patients, – the press service of the TASS company is quoted as saying.
Volunteers will receive two doses of the vaccine within 28 days. The first 20 participants will be injected with a real drug. The placebo will be used in the next stages of the trial.
According to the press service of NTI, preclinical studies of Betuvax-Kov-2 showed good efficiency with high antibodies against coronavirus. The clinical trials are expected to involve 116 volunteers aged 18 to 60 years old and without chronic diseases.
